PCM
REGN icon

Pentwater Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Pentwater Capital Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-6,500
Closed -$3.63M – 269
2021
Q2 		$3.63M Hold
6,500
– – 0.03% 119
2021
Q1 		$3.08M Hold
6,500
– – 0.03% 148
2020
Q4 		$3.14M Hold
6,500
– – 0.04% 105
2020
Q3 		$3.64M Hold
6,500
– – 0.05% 97
2020
Q2 		$4.05M Buy
+6,500
New +$3.69M 0.07% 56

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Pentwater Capital Management's REGN Position: Q3 2021 in Review

Pentwater Capital Management sold out of Regeneron Pharmaceuticals (REGN) in Q3 2021, closing a stake of 6,500 shares — an estimated $3.63M sold.

Pentwater Capital Management first reported a position in REGN in Q2 2020 and held it in 5 quarters. The position peaked at $4.05M in Q2 2020. 1,019 funds tracked by Wall St. Rank hold REGN as of Q3 2021.

  • Pentwater Capital Management reported no remaining Regeneron Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Pentwater Capital Management sold 6,500 Regeneron Pharmaceuticals shares in Q3 2021, an estimated $3.63M.
  • Pentwater Capital Management first reported a position in Regeneron Pharmaceuticals in Q2 2020 and held it in 5 quarters.
  • Pentwater Capital Management's Regeneron Pharmaceuticals position peaked at $4.05M in Q2 2020.
  • 1,019 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2021.

Based on Pentwater Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.